This study investigates the variability in cancer diagnosis across different tissues and organs, with a focus on the role of diagnostic methods such as Hematoxylin and Eosin (H&E) staining and immunohistochemistry (IHC). The predominance of female breast cancer (30%) aligns with global trends, underscoring the need for robust diagnostic protocols, particularly in developing regions. Other prevalent cancers, including skin, stomach, and cervix uteri, reflect a mix of environmental, genetic, and infectious factors. The underrepresentation of gallbladder and thyroid cancers (<1%) suggests potential underdiagnosis or lower prevalence. Age distribution data indicate peak cancer incidence in individuals aged 31 - 45 years, with gender-specific cancers like breast and cervical cancer predominantly affecting females (63.4%). The analysis also highlights significant diagnostic gaps, as 61.2% of cases did not undergo IHC testing due to resource constraints, leading to potential biases in cancer prevalence and diagnostic accuracy. The study emphasizes the complementary role of IHC in confirming ambiguous H&E findings, with strong alignment observed when both methods were used. However, the absence of IHC in many cases limits the robustness of conclusions, suggesting the need for increased access to IHC testing. The findings advocate for integrating IHC into routine diagnostics, expanding diagnostic capabilities, and improving sample sizes to ensure more reliable and comprehensive cancer data.
References
[1]
Smith, J. (2023) The Role of Immunohistochemistry in Cancer Diagnosis. In Cancer Diagnostics: Techniquesand Applications, Springer, 30-50.
[2]
Abd-Elkareem, S. (n.d.) Understanding the Distribution and Localization of Biomarkers in Tissues.
[3]
Kim, S., Park, J. and Choi, J. (2016) Exploring the Significance of Biomarkers in Clinical Practice. Journal of Clinical Oncology, 34, 411-416.
[4]
Parkin, D.M., Boyd, L. and Walker, L.C. (2014) Estimating the Global Burden of Cancer 2012. Cancer Journal for Clinicians, 64, 291-293.
[5]
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A. and Jemal, A. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: ACancerJournalforClinicians, 68, 394-424. https://doi.org/10.3322/caac.21492
[6]
Arnold, M., Sierra, M.S., Laversanne, M., Soerjomataram, I. and Ferlay, J. (2020) Global Cancer Incidence and Mortality Patterns in 2018: Global Cancer Observatory Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 70, 313-333.
[7]
Bhagat, A. and Schneider, S. (2013) Immunohistochemistry: A Vital Tool in Histopathology. JournalofClinicalPathology, 66, 551-558.
[8]
Ferlay, J., Shin, H. R., Bray, F., Forman, D., Mathers, C. and Parker, D. (2019) Globocan 2018: Global Cancer Observatory: Cancer Today. International Agency for Re-search on Cancer. https://gco.iarc.fr/today
[9]
Smith, A. & Johnson, B. (2023) Global Trends in Cancer Incidence: The Role of Breast Cancer in Developing Regions. Cancer Research Journal, 45, 120-135.
[10]
Haque, M., Shafique, M. and Qureshi, S. (2021) A Comprehensive Assessment of the Efficiency of Immunohistochemistry in Oncology. JournalofPathology, 254, 346-355. https://doi.org/10.1002/path.5782
[11]
Lakhani, S.R., Ellis, I.O. and Schnitt, S.J. (2019) The Role of H&E Staining in Breast Cancer Diagnosis: Implications for Clinical Management. BreastCancerResearch, 21, 93.
[12]
Pilar, A.D. and Zettler, C. (2020) Challenges in Immunohistochemistry Standardization. DiagnosticPathology, 15, 1-8.
[13]
Shafique, M., Ishaq, M.J. and Ullah, A. (2023) Immunohistochemistry in Cancer Diagnosis and Research: A Review. CancerManagementandResearch, 15, 1-12.
[14]
Tavakol, M. and Dennick, R. (2011) Making Sense of Cronbach’s Alpha. InternationalJournalofMedicalEducation, 2, 53-55. https://doi.org/10.5116/ijme.4dfb.8dfd